Department of Oncological Sciences, Icahn School of Medicine At Mount Sinai, New York, 10029, USA.
Immunotherapy Research Center, Houston Methodist Research Institute, Houston, TX, 77030, USA.
Cancer Immunol Immunother. 2021 Dec;70(12):3435-3449. doi: 10.1007/s00262-021-02927-2. Epub 2021 Apr 20.
Specific extracts of selected vegetables (SV) have been shown to benefit the survival of stage IIIb/IV non-small cell lung cancer patients in phase I/II studies and is currently in a phase III trial. However, the underlying mechanism of SV-mediated antitumor immune responses has not been elucidated. Our results indicate that SV modulated the NK and adoptive T cell immune responses in antitumor efficacy. Furthermore, antitumor effects of SV were also mediated by innate myeloid cell function, which requires both TLR and β-glucan signaling in a MyD88/TRIF and Dectin-1-dependent manner, respectively. Additionally, SV treatment reduced granulocytic myeloid-derived suppressor cell (MDSC) infiltration into the tumor and limited monocytic MDSC toward the M2-like functional phenotype. Importantly, SV treatment enhanced antigen-specific immune responses by augmenting the activation of antigen-specific TH1/TH17 cells in secondary lymphoid organs and proliferative response, as well as by reducing the Treg population in the tumor microenvironment, which was driven by SV-primed activated M-MDSC. Our results support the idea that SV can subvert immune-tolerance state in the tumor microenvironment and inhibit tumor growth. The present study suggests that features, such as easy accessibility, favorable clinical efficacy, no detectable side effects and satisfactory safety make SV a feasible, appealing and convincing adjuvant therapy for the treatment of cancer patients and prevent tumor recurrence and/or metastases.
一些选定蔬菜(SV)的特定提取物已在 I/II 期研究中显示出有利于 IIIb/IV 期非小细胞肺癌患者的生存,目前正在进行 III 期试验。然而,SV 介导的抗肿瘤免疫反应的潜在机制尚未阐明。我们的结果表明,SV 调节了 NK 和过继性 T 细胞的抗肿瘤免疫反应。此外,SV 的抗肿瘤作用还通过先天髓样细胞功能介导,这需要 TLR 和β-葡聚糖信号分别以 MyD88/TRIF 和 Dectin-1 依赖的方式进行。此外,SV 治疗减少了肿瘤中粒细胞性髓源抑制细胞(MDSC)的浸润,并限制单核细胞 MDSC 向 M2 样功能表型转化。重要的是,SV 治疗通过增强次级淋巴器官和增殖反应中抗原特异性 TH1/TH17 细胞的激活,以及通过减少肿瘤微环境中的 Treg 群体,增强了抗原特异性免疫反应,这是由 SV 激活的激活型 M-MDSC 驱动的。我们的研究结果支持这样一种观点,即 SV 可以颠覆肿瘤微环境中的免疫耐受状态并抑制肿瘤生长。本研究表明,SV 具有易于获得、临床疗效良好、无明显副作用和令人满意的安全性等特点,使其成为治疗癌症患者和预防肿瘤复发和/或转移的可行、有吸引力和令人信服的辅助治疗方法。